GlassScriptPhysician profile
Sarah L Bruner
NPI 1710104229
$2,633.20
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $399 · 2022: $547 · 2023: $822 · 2024: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,687.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $991.15 | 2021-2024 | |
| Lilly USA, LLC | $311.82 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $191.16 | 2021-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $162.49 | 2021-2024 | Breztri, Farxiga, Airsupra |
| Organon LLC | $158.36 | 2022 | |
| Mayne Pharma Commercial LLC | $87.35 | 2023 | |
| Myriad Women'S Health, INC. | $67.01 | 2023 | Myrisk |
| Exact Sciences Corporation | $59.72 | 2023-2024 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $59.07 | 2021-2024 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.49 | 2023-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.16 | 2021-2023 | Jardiance |
| Abbott Laboratories | $44.81 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $42.56 | 2021 | |
| Sanofi-Aventis U.S. LLC | $42.27 | 2021 | |
| Astellas Pharma US INC | $37.65 | 2023-2024 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $36.14 | 2022 | |
| Pfizer INC. | $35.57 | 2021-2023 | |
| Shield Therapeutics INC | $35.52 | 2024 | |
| Glaxosmithkline, LLC. | $30.27 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $27.97 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $24.51 | 2021 | |
| Nestle Healthcare Nutrition INC. | $23.27 | 2021 | |
| Linus Health, INC. | $18.13 | 2022 | |
| Amgen INC. | $17.94 | 2023 | Prolia, Evenity |
| Exeltis, USA INC. | $14.05 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Bruner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.